Malaria Malaria elimination Vivax malaria Mass primaquine preventive treatment
Conditions
Interventions
A dose of 0.25-
0.50 mg/kg of PQ will be administered daily for 14 days to all volunteers in Group 1 (who will receive PQ treatment in Year 1) aged 7 years and above with a normal G6PD test result. Volunteers in Grou
Experimental Drug,No Intervention No treatment
Mass Primaquine Preventive Treatment (MPPT),Control group
Sponsors
Faculty of Tropical Medicine, Mahidol University
Eligibility
Sex/Gender
All
Age
1 Years to No maximum
Inclusion criteria
Inclusion criteria: For Observational study: 1. Both male and female 2. Age 18 years old or above For Implementation study: 1. Both male and female 2. Age 1 year old or above
Exclusion criteria
Exclusion criteria: For Observational study: 1. Not willing to participate in the study 2. Unable to provide information either due to physical or mental conditions For Implementation study: Regarding participating in cohort 1. Not willing to participate in the study 2. Mental Illness and prisoners Regarding drug administration: 1. Not willing to take primaquine 2. Pregnant and lactating women 3. For those age 7 years or older who has G6PD abnormal 4. Have history of allergy to primaquine 5. Have history of drug reaction, such as hemolysis or dark urine, after having primaquine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in malaria incidence Year 1 = Month 1, Month 5 and Month 9; Year 2 = Month 1, Month 5 and Month 9; Passive Case Detectio a) The clinical malaria incidence rates, b) the Plasmodium prevalence rates,Cost estimates for MPPT implementation Monthly/Real time Costs spent for intervention and additional MPPT activities | — |
Secondary
| Measure | Time frame |
|---|---|
| Baseline prevalence of G6PD deficiency in the study population Prior to PQ administration for each group G6PD-RDT,Rates of primaquine-induced hemolysis in females Day 1, 2, 4, 6, 7 and 28 of PQ treatment Hemoglobin level,Impact of MPPT on parasite genetic diversity and relapse rates Year 1 = Month 1, Month 5 and Month 9; Year 2 = Month 1, Month 5 and Month 9; Passive case detectio Genotyping by deep sequencing of malaria parasites,Morbidity data 6-month prior to MPPT (PQ administration), during 1st and 2nd MPPT, 6-month after MPPT intervention Monthly morbidity data of reportable diseases from the surveillance system | — |
Countries
Thailand
Contacts
Public ContactAssoc. Prof. Jaranit Kaewkungwal
Faculty of Tropical Medicine, Mahidol University
Outcome results
None listed